GenVec was notified by its collaborator Novartis that FDA has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
AbbVie and Bristol-Myers Squibb announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC).
Following Revelations of ‘Flawed Studies’ in Clinical Trials, EMA Recommends Suspending Drugs; Many of Which Belong to Novartis AG and Teva
The European Medicines Agency recommended suspending the sale of dozens of generic medications, including several made by Novartis AG and Teva, following concerns over “flawed” studies conducted at a research facility in India.
On July 1, Cambridge, Massachusetts-based Bind Therapeutics announced that Pfizer had been approved as the stalking horse bidder for the majority of the company’s assets. The company has announced that two additional bidders had joined the auction.
An off-patent malaria drug could help to destroy cancer cells by making them more susceptible to radiotherapy, according to early research.
A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said in reporting an analysis of the results of a 10-year study.
Merck & Co. is under fire after more than 400 current and former female employees filed a $250 million class action lawsuit against the drug giant alleging gender discrimination and unequal pay.
Valeant Pharmaceuticals International said U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.
Amgen and UCB announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Scientists are opening a new front in the war on cancer with plans to develop “anti-evolution” drugs to stop tumor cells from developing resistance to treatment.